Fibroids are a common medical problem in women and cause more than 200,000 hysterectomies each year. Do you want to learn more? Visit Access Vascular Health: Michelle Maneevese, MD enlarged prostate treatment Houston. There are several types of treatment options for fibroids, including hysterectomy, abdominal myomectomy, laparoscopic myomectomy, and gonadotropin-releasing hormone agonists. In some cases, a combination of these treatments may be the best choice for a woman’s unique symptoms.
This procedure has shown to be effective in reducing the size of fibroids. It has been shown to reduce the volume by 50 percent within three months and 65 percent after one year. It also decreases the overall size of the uterus by 40 percent. The procedure itself is fast and painless, and most women are able to return to their regular activities 7 days after treatment.
The procedure was well tolerated, and adverse effects were minimal and non-significant. At one, three, and six months, significant reductions in SSS and fibroid volume were observed. At six months, the number of patients who underwent surgery decreased by nearly half. The NPV ratio was highly correlated with reductions in fibroid volume.
An FDA-approved focused ultrasound system called the ExAblate 2000 System has been approved to treat uterine fibroids. A pivotal study involving 192 symptomatic women concluded that this treatment had positive effects. It resulted in an average 10-point reduction in the Uterine Fibroid Quality of Life Questionnaire and a significant reduction in fibroid size at six months.
Fibroids are one of the most common obstetrical malignancies and can be treated through a variety of methods. One of these noninvasive procedures is high-intensity focused ultrasound, or HIFU. This technique combines high-intensity ultrasound waves with ultrasound to target fibroids. However, its efficacy is unclear. A systematic review compared the technique to other widely used clinical procedures.
The Halt Trial is another option for women with uterine fibroids. The trial enrolled 124 women with premenopausal symptoms and heavy menstrual bleeding. The researchers followed the patients for an average of 36 months after the procedure. The researchers also asked about pregnancy and surgical re-intervention.
While MRgHIFU is an effective treatment for fibroids, not all patients are candidates for this procedure. Patients with uterine fibroids should be evaluated carefully before undergoing the procedure. Although it is feasible for some patients, the method’s use in a small number of cases has limited its clinical utility.
Another option is to remove the fibroids. The most common method of removing uterine fibroids involves removing the fibroids using a surgical procedure. This procedure is considered minimally invasive and has a high safety profile. However, it is still an experimental treatment and requires more trials and a longer follow-up period.
In a recently published study, Desai et al. (2012) evaluated the efficacy of MRgHIFU in treating patients with fibroids. In this study, the investigators used the ExAblate MRgFUS system, manufactured by InSightec. Patients with fibroid symptoms were evaluated at baseline and 12 weeks following the procedure. In addition, the authors recorded adverse events that occurred during treatment.
Access Vascular Health: Michelle Maneevese, MD
5151 Katy Freeway Suite 170 Houston, TX 77007
Phone No. : 832-981-5781